As of January 1, 2018, Mr. Marc van Barneveld has left U-Needle’s Board, to fully focus on his product development company Factim BV.

Mr. Van Barneveld successfully led the company in the development of U-Needles first microneedle device “Bella-mu“, for which CE approval is expected in February 2018. Currently U-Needle shifts her focus from microneedle R&D towards clinical applications of Bella-mu and related products in the field of aesthetics, vaccination and diabetes.

In 2011 Mr. van Barneveld started the Bella-mu development for the Aesthetics field. After initial research years, to grow the technology with a small team of highly skilled developers, he successfully set-up the full scope ISO13485 quality system, leading to certification in 2016. Recently, U-Needle filed for CE approval of Bella-mu, completing the challenge Marc initially faced in 2011.

“We thank Marc for all he has done for the company and wish him all the best with Factim” said Mr. Wissink, U-Needle’s Founder and Managing Director, on behalf of all shareholders. “Missing his tremendous skills in product conceptualization and development, combined with his deep experience in engineering and tooling, will be a great loss to U-Needle.” From within Factim, Mr. Van Barneveld will remain involved in U-Needle to assist in product development and train younger colleagues to extend the U-Needle competences and use the generated Bella-mu knowledge for future generation microneedle devices.

Bonne chance Marc!



U-Needle develops proprietary microneedle technology applied in various user-friendly intradermal injection devices for aesthetics, vaccination and diabetes therapies.

The advanced microneedle technology facilitates fast therapy onset and reduced dose in pharmaceutical injectables.











Marc van Barneveld left Board of Directors

Leave a Reply

Your email address will not be published. Required fields are marked *